Paper Details

  1. Home
  2. Paper Details

Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.

Author: , BaiXuefan, ChenXinyue, FanRong, HouJinlin, NiuJunqi, PengJie, RenHong, ShengJifang, SunJian, TanDeming, TangHong, WangHao, WangMaorong, WuYaobo, XieQing, XuMin, ZhouBin

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated whether combining hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg) could predict off-treatment outcomes in patients with chronic hepatitis B (CHB) who stopped nucleos(t)ide analogue therapy. The combination of HBV RNA and HBcrAg was found to be a satisfactory predictor of clinical relapse and HBsAg loss after treatment cessation.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Safe nucleos(t)ide analogue discontinuation in chronic hepatitis B (CHB) is an unmet need. We aimed to investigate whether combining hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg) could perform satisfactorily in predicting off-treatment outcomes. METHODS: The ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/infdis/jiaa136

データ提供：米国国立医学図書館（NLM）

Stopping Hepatitis B Treatment: A Careful Approach

Imagine a desert oasis, where life thrives amidst the harsh environment. For patients with chronic hepatitis B (CHB), antiviral treatment is like that oasis, providing a sanctuary from the relentless viral assault. But the question remains: when is it safe to leave the oasis and venture back into the desert?

This study investigated the use of a combination of hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg) levels to predict the risk of relapse after stopping antiviral treatment in patients with CHB. The researchers found that patients who had both negative HBV RNA and low HBcrAg levels at the end of treatment were significantly less likely to experience a relapse compared to those with positive HBV RNA and high HBcrAg levels.

HBV RNA and HBcrAg: Navigating the Desert of Hepatitis B

This study provides valuable insights into the safe discontinuation of antiviral treatment for CHB. By carefully monitoring HBV RNA and HBcrAg levels, clinicians can better assess the risk of relapse and guide treatment decisions. It's like a desert nomad using a compass to navigate the changing landscape, ensuring they make informed decisions about their journey.

Implications for Hepatitis B Management and Patient Care

These findings have important implications for the management of CHB, allowing clinicians to personalize treatment plans and minimize the risk of relapse. It's like providing patients with a map and compass, empowering them to make informed decisions about their treatment journey and navigate the challenges of living with CHB.

Dr. Camel's Conclusion

This research underscores the importance of careful monitoring and individualized treatment plans for patients with CHB. By using a combination of HBV RNA and HBcrAg levels as a guide, we can navigate the complexities of antiviral treatment and provide patients with the best possible care. It's like a desert oasis, offering both a sanctuary from the harsh environment and a roadmap for navigating the journey ahead.

Date :
  1. Date Completed 2021-02-16
  2. Date Revised 2021-02-16
Further Info :

Pubmed ID

32211776

DOI: Digital Object Identifier

10.1093/infdis/jiaa136

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.